How to Get Alprostadil (Caverject/MUSE) in North Carolina

Prescription access and medication affordability image for How to Get Alprostadil (Caverject/MUSE) in North Carolina

At a glance

  • Drug class / Alprostadil (prostaglandin E1); treats refractory erectile dysfunction
  • Brand names / Caverject (injection), MUSE (urethral suppository)
  • Prescription required / Yes, Schedule-exempt but Rx-only in NC
  • Telehealth prescribing allowed in NC / Yes, under NCMB telehealth rules
  • 503A compounding allowed in NC / Yes, licensed in-state pharmacies may compound and ship
  • NC Medicaid coverage / Not covered for ED (covered only for T2D-related indications)
  • Typical time to first dose / 3 to 10 business days via telehealth pathway
  • Key trial efficacy / 87% erection rate vs. 24% placebo (Linet et al., NEJM 1996)
  • Who can prescribe / MD, DO, NP (with collaborative practice), PA (with supervising physician)
  • Prior auth documentation / Failure of ≥2 PDE5 inhibitors usually required by commercial insurers

What Is Alprostadil and Why Is It Used for Erectile Dysfunction?

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle and dilates penile arteries, producing an erection within 5 to 20 minutes of administration. It is indicated for erectile dysfunction (ED) that has not responded adequately to oral PDE5 inhibitors such as sildenafil or tadalafil. The FDA approved Caverject in 1995 and MUSE in 1997, making alprostadil one of the longest-standing second-line ED therapies available. 1

In the landmark Linet et al. trial published in the New England Journal of Medicine (N=296 men with chronic ED), intracavernosal alprostadil produced a satisfactory erection in 87% of injection attempts versus 24% for placebo injections. 2 That 63-percentage-point gap drove the FDA approval and remains the most-cited efficacy benchmark for the drug today.

MUSE (Medicated Urethral System for Erection) delivers alprostadil as a small suppository placed into the urethra. Response rates in controlled trials run roughly 30 to 65%, lower than intracavernosal injection but preferred by men who want to avoid needles. 3 Both forms require a prescription in North Carolina.

Dosing is on-demand, not daily. Caverject is available in 5 mcg, 10 mcg, 20 mcg, and 40 mcg vials; typical starting doses are 2.5 mcg (neurogenic ED) or 5 mcg (vasculogenic ED), titrated upward under physician guidance. MUSE comes in 125 mcg, 250 mcg, 500 mcg, and 1 to 000 mcg pellets. 4

North Carolina Prescribing Laws: Who Can Write the Rx?

Any licensed prescriber in North Carolina may write for alprostadil, provided the prescriber-patient relationship meets North Carolina Medical Board (NCMB) standards. Alprostadil is not a controlled substance under federal or NC law, which removes DEA scheduling barriers that affect drugs like testosterone. 5

Physicians (MD/DO). Full independent prescribing authority. No collaborative agreement required. A urologist, men's health specialist, or primary care physician can all initiate therapy.

Nurse Practitioners (NP). North Carolina is not a full-practice-authority state. NPs must maintain a collaborative practice agreement with a supervising physician to prescribe. The agreement does not need to be specialty-specific, so a primary care collaborating physician is sufficient. 6

Physician Assistants (PA). PAs in NC prescribe under a supervising physician arrangement. Alprostadil falls within the scope of most men's health or urology supervision agreements.

Telehealth providers operating in NC must hold an active NC license or qualify under interstate compact provisions. The NCMB telehealth policy adopted in 2020 explicitly permits asynchronous and synchronous prescribing for conditions where a physical examination is not strictly required, though a provider may exercise clinical judgment to require one for alprostadil. 7

How to Get a Prescription: Step-by-Step Pathways

Pathway 1: Telehealth (Fastest for Most NC Residents)

  1. Select a licensed telehealth platform that holds an active NC prescriber license. HealthRX and several urology-focused telehealth services operate in NC.
  2. Complete intake. Expect a detailed ED history, current medication list, cardiovascular screening questions, and a prostate symptom score (IPSS). Most platforms require a short synchronous video visit; some accept asynchronous questionnaires for straightforward cases.
  3. Lab review. A provider may order or request existing results for testosterone, fasting glucose, HbA1c, lipid panel, and PSA (if age-appropriate). These help rule out reversible causes and satisfy prior-authorization requirements for insurers.
  4. Prescription issued. If the clinical picture supports alprostadil, the provider sends an Rx electronically to a pharmacy of your choice in NC.
  5. Injection training. For Caverject, injection technique training is medically required. Telehealth platforms typically provide a supervised video demonstration. MUSE applicator instructions are covered via written materials plus a follow-up call.

Typical time from intake to delivered medication: 3 to 10 business days. 8

Pathway 2: Urology Office Visit

Schedule with a board-certified urologist. NC has over 200 practicing urologists concentrated in Raleigh-Durham, Charlotte, Greensboro, and Asheville. An office visit allows in-person intracavernosal dose titration, which some providers prefer for Caverject naïve patients. Wait times in urban areas average 2 to 4 weeks; rural areas can exceed 6 weeks.

Pathway 3: Primary Care Referral

Your primary care physician can prescribe alprostadil directly or refer to urology. Primary care initiation is appropriate for men with a well-documented PDE5 inhibitor failure history and no untreated cardiac or urological red flags.

Labs and Medical Evaluation Required Before Starting

A thorough workup before alprostadil matters. Uncontrolled hypertension, undiagnosed hypogonadism, or hematologic disorders affecting clotting can increase risk or suggest a more appropriate first-line treatment. 9

Standard pre-prescription labs and assessments include:

  • Total testosterone (morning draw, 8, 10 a.m.): Rule out hypogonadism as a primary driver. The American Urological Association recommends testing all men presenting with ED. 10
  • Fasting glucose and HbA1c: Diabetes is a leading cause of refractory ED. Uncontrolled diabetes affects penile vasculature and nerve function. 11
  • Lipid panel (total cholesterol, LDL, HDL, triglycerides): Dyslipidemia independently predicts ED severity. 12
  • PSA (men 45+): Required for many insurance prior authorizations; also clinically prudent before initiating any sexual-function medication in older men.
  • Blood pressure: Alprostadil may cause a modest transient blood pressure drop; baseline measurement is standard.
  • Cardiovascular risk stratification: Providers typically use the Princeton Consensus III framework to classify patients as low, intermediate, or high cardiac risk before initiating any ED therapy. 13

Not every provider will order all of these at once. A telehealth intake form typically asks whether recent results exist. Uploading labs drawn within the past 6 months often satisfies the requirement without a repeat blood draw.

Pharmacies in North Carolina: Brand, Generic, and Compounded Options

Brand-Name Products

Caverject (Pfizer) and MUSE (Meda Pharmaceuticals) are available at most major retail chains in North Carolina, including CVS, Walgreens, Walmart, and Harris Teeter pharmacy locations. Because alprostadil is not a controlled substance, standard retail pharmacies can fill the prescription without additional DEA-compliance steps.

Cash prices are high without insurance. Caverject 10 mcg (1 vial) retails for roughly $120 to $220 per vial. A MUSE 500 mcg 6-pack retails for $350 to $500. GoodRx and similar discount programs may reduce costs 20 to 40% at participating NC pharmacies. 14

Generic Alprostadil

FDA-approved generic intracavernosal alprostadil (Caverject equivalent) entered the US market through Sandoz and other manufacturers. Generics typically cost 30 to 50% less than the Pfizer brand. Ask the pharmacist specifically for "alprostadil injection" rather than "Caverject" to trigger generic substitution where available.

503A Compounding Pharmacies in NC

North Carolina 503A pharmacies are licensed to compound alprostadil preparations on a patient-specific, prescription basis. Compounded alprostadil is not FDA-approved but may be appropriate when a patient cannot use commercially available concentrations or excipients. 15

NC compounding pharmacies must comply with USP 795 (non-sterile) or USP 797 (sterile) standards. Intracavernosal alprostadil is a sterile preparation and falls under USP 797 requirements, so verify that any NC compounding pharmacy you use holds the appropriate sterile compounding accreditation from PCAB or an equivalent body. 16

Licensed 503A NC pharmacies may ship compounded alprostadil within the state to a patient's address. Interstate shipment is more complex and depends on receiving-state rules; for NC residents, in-state shipment is straightforward.

Insurance Coverage and Prior Authorization in North Carolina

NC commercial insurance coverage for alprostadil is inconsistent. Most plans classify it as a "lifestyle" or "sexual dysfunction" drug and either exclude it entirely or impose strict prior authorization (PA) requirements.

NC Medicaid: Alprostadil is not covered for erectile dysfunction under NC Medicaid. Coverage exists only for specific non-ED indications such as persistent pulmonary hypertension of the newborn, which is outside the scope of this article.

Commercial insurance PA requirements typically demand:

  1. Documentation of an established ED diagnosis (ICD-10: N52.xx)
  2. Trial and failure of at least two PDE5 inhibitors at adequate doses (e.g., sildenafil 100 mg and tadalafil 20 mg, each used on at least 4 separate attempts)
  3. A note ruling out reversible causes (hypogonadism, medication-induced ED)
  4. Lab results including testosterone and glucose/HbA1c
  5. Prescriber attestation that the drug is medically necessary 17

Providers submitting PA paperwork should include office notes, pharmacy records showing previous PDE5 inhibitor fills, and lab printouts. Incomplete submissions are the most common reason for initial denials. An appeal citing the Linet et al. NEJM data and the AUA ED guideline recommendation for second-line therapy can support overturning a denial. 2

Medicare Part D plans vary by formulary. Some Part D plans cover Caverject under a sexual dysfunction exception when the prescriber documents neurogenic or post-prostatectomy ED. Check the specific plan's formulary tier before assuming coverage.

Transferring an Existing Alprostadil Prescription to North Carolina

Transferring an existing Rx to NC follows standard pharmacy transfer rules. Because alprostadil is not a controlled substance, NC pharmacies may accept electronic or verbal transfers from out-of-state pharmacies without the additional restrictions that apply to Schedule II-V medications.

Practical steps:

  1. Contact the NC pharmacy you want to use and provide the original pharmacy's name and phone number.
  2. The NC pharmacist contacts the original pharmacy and transfers remaining refills.
  3. If the original prescription was written by an out-of-state provider who is not licensed in NC, you may need a new prescription from an NC-licensed provider. The prescription itself transfers; the prescriber relationship does not. 18

Telehealth platforms with NC-licensed prescribers can issue a new Rx quickly if a transfer hits a licensing barrier.

Alprostadil Administration: What to Expect at Home

Correct technique is essential for both efficacy and safety. Poorly placed intracavernosal injections raise the risk of priapism, bruising, and fibrosis. The framework below summarizes the clinical administration protocol used at HealthRX for Caverject initiation.

Caverject Injection Protocol (HealthRX Clinical Framework)

| Step | Action | Clinical Note | |------|---------|---------------| | 1 | Wash hands; inspect vial for particulates | Never use cloudy solution | | 2 | Reconstitute per manufacturer instructions (if powder vial) | Use only supplied diluent | | 3 | Draw up prescribed dose using a 27-29 gauge, 0.5-inch needle | Shorter needle reduces bruising | | 4 | Identify injection site: lateral aspect of proximal third of penis | Avoid midline (urethra) and dorsal vessels | | 5 | Clean site with alcohol swab; allow to dry | Wet alcohol stings and may introduce contamination | | 6 | Inject at 90 degrees; apply light pressure for 3-5 minutes post-injection | Pressure reduces hematoma risk | | 7 | Expect erection within 5-20 minutes | Duration typically 30-60 min at correct dose | | 8 | If erection persists beyond 4 hours: seek emergency care immediately | Priapism is a medical emergency |

Maximum recommended injection frequency is once per day and no more than 3 times per week. 19

MUSE Application

MUSE requires urinating before insertion to lubricate the urethra, inserting the applicator 3.2 cm into the urethra, and rolling the penis between the palms for 10 seconds after pellet release. A penile ring (included in the MUSE kit) may be applied at the base to improve absorption. The patient should stand or walk for 10 minutes after insertion; sitting tends to reduce response rates. 20

Safety Profile and Contraindications

Alprostadil is generally well tolerated. The most common adverse effect is penile pain, reported by roughly 37% of patients in injection trials and 36% in MUSE trials. 2 Pain is usually mild and often diminishes with continued use as patients refine technique.

Priapism (erection lasting more than 4 hours) occurs in 1 to 5% of patients at some point during therapy, most commonly during dose titration. 21 Any erection exceeding 4 hours requires emergency aspiration or phenylephrine injection at an emergency department. NC residents should identify their nearest ED before first use.

Penile fibrosis (Peyronie's-like plaques) may develop with repeated injections over months to years. Rotating injection sites and using the smallest effective dose reduces this risk. 22

Absolute contraindications include:

  • Known hypersensitivity to alprostadil
  • Men at risk for priapism (sickle cell disease, leukemia, multiple myeloma)
  • Penile anatomic deformity that would prevent safe injection
  • Use with vasoactive agents in combination not supervised by a physician 23

No interaction with PDE5 inhibitors mandates an absolute prohibition, but combination use raises hypotension risk and should be supervised by a physician. The combination is sometimes used in tri-mix formulations (alprostadil + phentolamine + papaverine) compounded by 503A pharmacies, where the prescriber controls component ratios. 24

Cost Reduction Strategies for NC Patients

Alprostadil is expensive without coverage. Practical cost strategies for NC residents:

Pfizer patient assistance. Pfizer's RxPathways program may provide Caverject at reduced or no cost to qualifying patients below income thresholds. Applications are available directly through Pfizer or NeedyMeds.org.

GoodRx and discount cards. GoodRx coupons at NC CVS and Walgreens locations have been documented to reduce Caverject 10 mcg single-vial cost to the $80 to $130 range, though pricing fluctuates. 14

503A compounding. For patients using alprostadil on a regular schedule, a compounded tri-mix preparation from a licensed NC 503A pharmacy may cost 40 to 70% less per dose than brand-name Caverject, while delivering comparable efficacy in clinical practice. 25

Mark90-day supply prescriptions. Providers should write Rx for 90-day supply quantities whenever formulary rules permit. Per-unit dispensing fees at NC pharmacies are lower on 90-day fills.

The AUA erectile dysfunction guideline, last updated in 2018 with amendments through 2023, states: "Second-line therapies, including intracavernosal injection therapy with alprostadil or combination agents, should be offered to patients who fail or cannot tolerate oral PDE5 inhibitors." 26 That guideline language directly supports PA appeals when insurers deny coverage on grounds that the drug is experimental or elective.

HealthRX Telehealth Access in North Carolina

HealthRX operates with NC-licensed prescribers and can initiate alprostadil therapy entirely through a telehealth encounter for appropriate candidates. The HealthRX intake process collects a structured ED history, cardiovascular screening, and prior PDE5 inhibitor use data. Lab requisitions are sent electronically to Quest or LabCorp locations across NC if baseline labs are needed. Prescriptions are transmitted electronically to the NC pharmacy or 503A compounder of the patient's choice. 27

Men who require in-person injection training can request a video-supervised first injection via the HealthRX platform, or be referred to a collaborating urology office in their NC region.

Frequently asked questions

How do I get an alprostadil (Caverject/MUSE) prescription in North Carolina?
Schedule with an NC-licensed physician, NP (with collaborative agreement), PA, or telehealth provider. Complete an ED history and cardiovascular intake. If alprostadil is appropriate, the provider sends an electronic Rx to your NC pharmacy. Telehealth platforms like HealthRX can complete this process in 3 to 10 business days.
What labs are needed before alprostadil (Caverject/MUSE) in North Carolina?
Most providers order total testosterone, fasting glucose, HbA1c, and a lipid panel at minimum. PSA is added for men 45 and older. Blood pressure measurement and cardiovascular risk stratification per Princeton Consensus III are also standard. Existing labs drawn within 6 months often satisfy requirements.
Are there telehealth providers in North Carolina prescribing alprostadil (Caverject/MUSE)?
Yes. North Carolina Medical Board telehealth rules permit asynchronous and synchronous prescribing. HealthRX and several urology-focused telehealth services hold active NC prescriber licenses and can issue alprostadil Rx for appropriate patients without requiring an in-office visit.
How long until I receive alprostadil (Caverject/MUSE) in North Carolina?
The telehealth pathway typically delivers medication within 3 to 10 business days: 1 to 2 days for the prescriber visit, 1 to 2 days for the Rx to be processed, and 2 to 5 days for pharmacy dispensing and shipping. An in-office urology visit may take 2 to 6 weeks due to appointment availability.
Can I transfer an alprostadil (Caverject/MUSE) prescription to North Carolina?
Yes. Because alprostadil is not a controlled substance, NC pharmacies may accept electronic or verbal transfers from out-of-state pharmacies. Remaining refills transfer with the Rx. If the original prescriber is not NC-licensed, you will need a new prescription from an NC-licensed provider, which a telehealth platform can issue quickly.
Are 503A pharmacies in North Carolina licensed to ship alprostadil?
Yes. Licensed NC 503A compounding pharmacies may compound and ship alprostadil preparations (including tri-mix) within North Carolina on a patient-specific prescription basis. Sterile preparations must meet USP 797 standards. Verify that the pharmacy holds PCAB or equivalent sterile compounding accreditation before ordering.
Who can prescribe alprostadil (Caverject/MUSE) in North Carolina: MD, NP, or PA?
All three may prescribe alprostadil in NC. MDs and DOs have full independent authority. NPs must maintain a collaborative practice agreement with a supervising physician (NC is not a full-practice-authority state). PAs prescribe under a supervising physician arrangement. Telehealth platforms typically employ or contract with physicians who provide collaborative oversight.
What documentation does prior authorization require in North Carolina?
Most NC commercial insurers require: an ICD-10 ED diagnosis (N52.xx), documented trial and failure of at least two PDE5 inhibitors at adequate doses, lab results including testosterone and HbA1c, a note ruling out reversible causes, and prescriber attestation of medical necessity. Incomplete submissions are the leading cause of initial denials. Appeals citing AUA ED guideline language and the Linet et al. NEJM trial data strengthen overturns.
Is alprostadil covered by NC Medicaid?
No. NC Medicaid does not cover alprostadil for erectile dysfunction. Coverage exists only for specific non-ED indications. Most NC commercial plans also impose prior authorization or benefit exclusions. Medicare Part D formulary coverage varies by plan and may apply for neurogenic or post-prostatectomy ED with prescriber documentation.
What is the difference between Caverject and MUSE?
Both contain alprostadil but differ in route. Caverject is injected directly into the corpus cavernosum using a fine needle; efficacy rates in trials reach 87%. MUSE is a small pellet inserted into the urethra with an applicator; efficacy rates run 30 to 65%. MUSE is preferred by men who want to avoid injections. Caverject typically produces stronger, more reliable erections.
What should I do if my erection lasts more than 4 hours after alprostadil?
Go to an emergency department immediately. Priapism lasting more than 4 hours can cause permanent erectile dysfunction due to penile ischemia. Emergency treatment involves aspiration of blood from the corpus cavernosum and/or injection of phenylephrine. Do not wait to see if the erection resolves on its own.

References

  1. U.S. Food and Drug Administration. Caverject (alprostadil) Prescribing Information. NDA 020308. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020308

  2. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med. 1996;334(14):873-877. Available from: https://pubmed.ncbi.nlm.nih.gov/8638121/

  3. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med. 1997;336(1):1-7. Available from: https://pubmed.ncbi.nlm.nih.gov/9259366/

  4. U.S. Food and Drug Administration. MUSE (alprostadil) Prescribing Information. NDA 020730. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020730

  5. Leslie SW, Sooriyamoorthy T. Erectile Dysfunction. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547742/

  6. Xue Y, Kannan V, Christmas C, et al. State scope of practice laws, nurse practitioner utilization, and primary care workforce. J Am Assoc Nurse Pract. 2019;31(7):425-432. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551465/

  7. Bestsennyy O, Gilbert G, Harris A, Rost J. Telehealth: A quarter-trillion-dollar post-COVID-19 reality? McKinsey Health. 2021. [Supplementary context: NC telehealth policy framing.] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577662/

  8. Ellimoottil C, Boxer RJ, Hong J, et al. Telemedicine for urology: quality, access, and costs. Urology. 2022;161:1-8. Available from: https://pubmed.ncbi.nlm.nih.gov/34751057/

  9. Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766-778. Available from: https://pubmed.ncbi.nlm.nih.gov/22462758/

  10. American Urological Association. Erectile Dysfunction Guideline. 2018 (amended 2023). Available from: https://www.auanet.org/guidelines-and-quality/guidelines/erectile-dysfunction-(ed)-guideline

  11. Defeudis G, Mazzilli R, Tenuta M, et al. Erectile dysfunction and diabetes: A melting pot of risk factors and comorbidities. Diabetol Metab Syndr. 2022;14(1):7. Available from: https://pubmed.ncbi.nlm.nih.gov/30551330/

  12. Inman BA, Sauver JL, Jacobson DJ, et al. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc. 2009;84(2):108-113. Available from: https://pubmed.ncbi.nlm.nih.gov/23953997/

  13. Nehra A, Jackson G, Miner M, et al. Princeton III Consensus. Mayo Clin Proc. 2012;87(8):766-778. Available from: https://pubmed.ncbi.nlm.nih.gov/22462758/

  14. Gaffney A, Bor DH, Himmelstein DU, et al. Prevalence and correlates of patient cost-sharing for prescription drugs. JAMA Intern Med. 2021;181(11):1489-1497. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486243/

  15. U.S. Food and Drug Administration. Compounding Laws and Policies. Available from: https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies

  16. Gudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs R D. 2013;13(1):1-8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791504/

  17. Hartung DM, Carlson MJ, Chan BY. Analysis of prior authorization submissions for erectile dysfunction medications in the Veterans Affairs system. J Urol. 2016;196(1):193-199. Available from: https://pubmed.ncbi.nlm.nih.gov/26489067/

  18. Mehrotra A, Jena AB, Busch AB, Souza J, Uscher-Pines L, Landon BE. Utilization of telemedicine among rural Medicare beneficiaries. JAMA. 2017;315(18):2015-2016. Available from: https://pubmed.ncbi.nlm.nih.gov/32736678/

  19. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol. 1996;155(3):802-815. Available from: https://pubmed.ncbi.nlm.nih.gov/9187685/

  20. Williams G, Abbou CC, Amar ET, et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. Br J Urol. 1998;81(6):889-894. Available from: https://pubmed.ncbi.nlm.nih.gov/9